Northside Hospital, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.northside.com
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Northside Hospital, Inc.
- Registration Number
- NCT06337331
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT06046248
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05909059
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05519579
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
Recruiting
- Conditions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05417971
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Use of Convalescent Plasma for COVID-19
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04408040
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
GM-CSF With Post-Transplant Cyclophosphamide
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04237623
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Ibrutinib and Rituxan for Chronic GVHD
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04235036
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02828592
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02771197
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
© Copyright 2024. All Rights Reserved by MedPath